Profile
Roger Tell is currently the Director at Vivesto AB since 2022 and the Chief Scientific & Medical Officer at Isofol Medical AB since 2019.
Previously, he worked as the Vice President-Clinical Development at Aprea Therapeutics AB. Dr. Tell obtained his doctorate degree from Karolinska Institutet in 1998.
Roger Tell active positions
| Companies | Position | Start |
|---|---|---|
| ISOFOL MEDICAL AB | Chief Tech/Sci/R&D Officer | 31/01/2019 |
| VIVESTO AB | Director/Board Member | 24/05/2022 |
Former positions of Roger Tell
| Companies | Position | End |
|---|---|---|
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops novel anticancer compounds | Corporate Officer/Principal | 31/01/2019 |
Training of Roger Tell
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
Karolinska Institutet
Karolinska Institutet Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vivesto AB
Vivesto AB Pharmaceuticals: GenericHealth Technology Develops cancer drugs based on nanotechnology for human and veterinary use | Health Technology |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops novel anticancer compounds | Health Technology |
Isofol Medical AB
Isofol Medical AB Pharmaceuticals: MajorHealth Technology Provides novel folate-based pharmaceutical products | Health Technology |
- Stock Market
- Insiders
- Roger Tell
















